Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q15643
UPID:
TRIPB_HUMAN
Alternative names:
Clonal evolution-related gene on chromosome 14 protein; Golgi-associated microtubule-binding protein 210; Trip230
Alternative UPACC:
Q15643; B2RUT2; O14689; O15154; O95949; Q6MZL5
Background:
Thyroid receptor-interacting protein 11, also known as Golgi-associated microtubule-binding protein 210, plays a pivotal role in vesicle tethering to Golgi, crucial for Golgi structure and function. It facilitates both anterograde and retrograde trafficking in the early secretory pathway, impacting ER-to-Golgi and Golgi complex operations. Additionally, it binds the thyroid receptor in the presence of triiodothyronine, enhancing transcription.
Therapeutic significance:
Linked to diseases such as Achondrogenesis 1A and Odontochondrodysplasia 1, which involve skeletal and dental development issues, understanding the role of Thyroid receptor-interacting protein 11 could open doors to potential therapeutic strategies.